ArticleMolecular biology reports2025
Level of DNA damage in peripheral blood mononuclear cells in endometrial cancer patients according to histological type and tumor differentiation.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenetic damage is a hallmark of cancer and plays a crucial role in the pathogenesis and progression of endometrial cancer (EC). This study aimed to evaluate the level of DNA damage, measured as the genetic damage index (GDI), in peripheral blood mononuclear cells (PBMCs) of patients with EC and to examine its relationship with clinical and pathological features. METHODS AND
resultsA total of 88 women were enrolled, including 58 with newly diagnosed EC and 30 healthy controls. DNA damage was assessed using the alkaline comet assay. GDI was calculated and examined in relation to age, body mass index (BMI), FIGO stage as defined by the International Federation of Gynecology and Obstetrics (2023), tumor grade, and histological type. Patients with EC showed significantly higher GDI compared to controls (p < 0.0005). GDI increased progressively with tumor grade and was significantly elevated in serous/clear cell cancer versus endometrioid type (p = 0.032). Although GDI was higher across tumor stages compared to controls, no significant differences were found between individual stages. A significant increase in GDI was also observed in patients with BMI ≥ 40 compared to those with BMI 25-29.9 (p = 0.010). Linear regression confirmed that tumor stage, tumor grade, and histological type were independent predictors of GDI (R² = 0.812).
conclusionsThe findings suggest that the level of DNA damage may serve as a valuable indicator of tumor biology in EC. Its association with key pathological features highlights its potential role in early diagnosis, prognostic assessment, and personalized treatment planning.
Indexed as
Identifiers
41296163What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.